SGI
1.11
59.7%
GUM
0.14
-22.2%
8IH
0.028
55.6%
MRD
0.038
-20.8%
ALM
0.009
50%
MMR
0.004
-20%
M2R
0.003
50%
RKB
0.004
-20%
LML
0.011
37.5%
RLG
0.004
-20%
QXR
0.004
33.3%
X2M
0.012
-20%
RNX
0.004
33.3%
D3E
0.325
-19.8%
NVA
1.145
33.1%
AUV
0.016
-15.8%
VBS
0.265
32.5%
AVW
0.011
-15.4%
FBM
0.056
30.2%
CC9
0.17
-15%
SDV
0.475
28.4%
PVT
0.017
-15%
AON
0.01
25%
CYQ
0.006
-14.3%
CAV
0.005
25%
DTI
0.012
-14.3%
ENT
0.005
25%
VKA
0.006
-14.3%
FBR
0.005
25%
ATR
0.7
-12.5%
TMX
0.005
25%
NNL
0.19
-11.6%
TMB
0.11
20.9%
DTM
0.04
-11.1%
ZNO
0.076
20.6%
FIN
0.008
-11.1%
OMX
0.1
20.5%
PIM
0.08
-11.1%
BLU
0.006
20%
TEM
0.008
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts